Last reviewed · How we verify
SB206 8%
At a glance
| Generic name | SB206 8% |
|---|---|
| Also known as | NVN1000 |
| Sponsor | Novan, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum (PHASE2)
- Topical NVN1000 for the Treatment of External Genital and Perianal Warts (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB206 8% CI brief — competitive landscape report
- SB206 8% updates RSS · CI watch RSS
- Novan, Inc. portfolio CI